MYCN has been shown to repress androgen receptor signaling in prostate cancer and can redirect the binding of the transcription factor enhancer of zeste homolog 2 (EZH2) to the MYCN promoter resulting in gene silencing [169]. This evidence concerns the gene MYCN and Familial prostate cancer.